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ABSTRACT 
The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) 
outcomes has remained debated. To address this issue, we assessed the impact of 
measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. 
Inclusion criteria included adult patients with acute myeloid (AML) or acute 
lymphoblastic leukemia (ALL), CBT as first allo-HCT in first or second complete 
remission (CR) at transplantation, and known MRD status at the time of CBT. Data from 
506 patients were included in the analysis. Among them, 317 patients had AML and 189 
had ALL. Positive MRD was reported in 169 (33%) patients while the remaining 337 
patients were MRD negative at CBT. At 2 years, relapse incidence was 18% in patients 
with MRD negativity versus 33% in those with MRD positivity at transplantation 
(P<0.001). Two-year leukemia-free survival (LFS) and overall survival (OS) were 57% 
and 60%, respectively, in MRD negative patients, versus 38% (P<0.001) and 48% 
(P=0.004), respectively, in those with MRD positivity. There was no interaction between 
the impact of MRD on OS and LFS and diagnosis (i.e. ALL versus AML), single or double 
CBT, and reduced-intensity or myeloablative conditioning. On multivariate analysis, 
MRD positivity was associated with a higher risk of relapse (HR=1.8, P=0.003), 
comparable non-relapse mortality (P=0.44), worse LFS (HR=1.4, P=0.008) and a trend 
towards worse OS (HR=1.3, P=0.065). In conclusion, these data suggest that novel 
strategies that are aiming to achieve MRD negativity at CBT are needed for leukemic 
patients with positive MRD pre-CBT.   
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CONDENSED ABSTRACT 
• Patients with detectable MRD pre-CBT have a higher risk of relapse than those 
without (HR=1.8, P=0.003).  
• Patients with detectable MRD pre-CBT have a lower LFS than those without 
(HR=1.4, P=0.008).  
 
BACKGROUND 
Allogeneic hematopoietic cell transplantation (allo-HCT) is the treatment of choice for fit 
patients with high-risk acute myeloid leukemia (AML) or acute lymphoblastic leukemia 
(ALL)1-8. Allo-HCT relies both on the conditioning regimen and on immune-mediated 
graft-versus-leukemia (GvL) effects for leukemia eradication9-11. Despite the rapid 
growth of T-cell replete HLA-haploidentical transplantation12, umbilical cord blood 
transplantation (CBT) has remained an alternative option for patients with high-risk 
acute leukemia without an HLA-identical sibling donor13-18. 
 During the last decade, several reports have highlighted the negative impact of 
detectable measurable residual disease (MRD) at transplantation on transplantation 
outcomes in patients transplanted from either HLA-matched related or unrelated 
donors, as well as in those given cells from HLA-haploidentical donors19-25. This 
remained true in patients in second complete remission (CR) at transplantation26. 
Interestingly, the negative impact of detectable MRD at transplantation holds true in 
large registry studies in which various techniques (depending on transplant center) 
were used for MRD detection21,27,28. However, a recent report has demonstrated a lower 
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incidence of relapse with double CBT than with HLA-matched transplantation among 
patients with detectable MRD at transplantation15. This is in line with emerging data 
suggesting higher GvL effects with CBT and one might question whether MRD has an 
impact on CBT outcome. 
 In this report, we assess the impact of detectable MRD at transplantation on CBT 
outcomes in a relatively large cohort of patients with acute leukemia in complete 
remission (CR) reported to the Acute Leukemia Working Party (ALWP) of the European 




Patients and inclusion criteria 
This is a retrospective study from the ALWP of the EBMT and from Eurocord. The EBMT 
registry is a voluntary working society of more than 500 transplant centers, participants 
of which are required once a year to report all consecutive hematopoietic stem cell 
transplantations and follow-up. Audits are routinely performed to check for data 
accuracy. Eurocord collects data on CBT carried out in more than 50 countries 
worldwide covering > 500 transplant centers (mainly EBMT).  
Inclusion criteria included adult patients (defined as ≥18 years of age at transplantation), with 
AML or ALL, single or double CBT as first allo-HCT from 2002-2017 in an EBMT-affiliated 
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center, in first or second CR at transplantation, and known MRD status at the time of 
transplantation. 
Reduced intensity conditioning (RIC) was defined as regimens combining 
fludarabine with either < 6 Gy total body irradiation (TBI), ≤ 8 mg/kg busulfan, or ≤ 140 
mg/m2 melphalan or with other nonmyeloablative drugs as previously reported 29. HLA-
compatibility included antigen level typing for HLA-A and -B and allele level typing for 
HLA-DRB1. Cord blood units were generally 4–6/6 HLA-A, -B and -DRB1 matched to the 
recipient. Acute and chronic graft-versus-host disease (GVHD) were graded according to 
previously reported criteria 30.   
 
MRD detection 
Several techniques with various thresholds were used for MRD detection, depending of 
the centers. For AML patients, data on MRD methodology was available for 115 patients 
from 30 centers (supplemental table 1). Most centers (22/30) used multiparameter 
flow-cytometry (MFC) and PCR techniques with or without next generation sequencing 
(NGS). The most frequent threshold used was 10-5 for PCR techniques and 10-4 for MFC 
(supplemental table 1). For ALL patients, data on MRD methodology was available for 73 
patients from 28 centers. Eighteen centers used MFC plus PCR techniques with or 
without NGS while 22 others used PCR techniques only. The most frequent threshold 
used was 10-5 for PCR techniques and 10-4 for MFC (supplemental table 1). 
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Statistical analyses 
Analyses were carried out on data from all patients meeting the inclusion/exclusion 
criteria. Start time was the day of CBT for all endpoints. Patients were censored at the 
time of last follow-up. Neutrophil engraftment was defined as the first of 3 consecutive 
days with a neutrophil count of at least 0.5 x 109/L. Relapse was defined as the presence 
of 5% bone marrow blasts and/or reappearance of the underlying disease. Non-relapse 
mortality (NRM) was defined as death without evidence of relapse or progression. 
Overall survival (OS) was defined as the time from CBT to death, regardless of the cause. 
The primary endpoint of the study was leukemia-free survival (LFS) according to MRD 
status. Events in the composite endpoint LFS included relapse and death, whichever 
occurred first. 
Cumulative incidence functions were used to estimate relapse incidence and NRM 
in a competing risk setting, because death and relapse compete with each other. To 
estimate the cumulative incidence of acute and chronic GVHD, we considered relapse 
and death to be competing events. Events in the composite endpoint GVHD-free and 
relapse free survival (GRFS) included grade III-IV acute GVHD, extensive chronic GVHD, 
relapse or death 31. The Kaplan-Meier method was used to estimate OS, LFS and GRFS.  
Univariate analyses were performed using Gray’s test for cumulative incidence 
functions and the log-rank test for OS, LFS and GRFS. Multivariate Cox models were used 
to adjust the comparison of transplantation outcomes in patients with, versus without, 
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evidence of MRD at transplantation for possible imbalance between groups. Factors 
included in the Cox models comprised detectable MRD or not, diagnosis (AML versus 
ALL), age, year of transplantation, second versus first CR, myeloablative versus RIC 
regimen, double versus single CBT, in vivo T cell depletion or not, and center (frailty). All 
tests were two sided. The type I error rate was fixed at 0.05 for determination of factors 
associated with time to event outcomes. Statistical analyses were performed with SPSS 
19 (SPSS Inc, Chicago, IL), and R 3.4.3 (R Development Core Team, Vienna, Austria) 




A total of 506 patients met the inclusion/exclusion criteria and were reported in the 
study (Table 1). Among them, 317 patients had AML and 189 had ALL (including 102 
patients with Philadelphia chromosome positive (Phi-pos) ALL). Patients received either 
single (n=227) or double unit CBT (n=279). Disease status was first CR in 320 patients 
and second CR in the remaining 186 patients. MRD positivity was detected in 169 (33%) 
patients while the remaining 337 patients were MRD negative at CBT. MRD was more 
frequently detected in ALL than in AML patients (P=0.02), in patients given single CBT 
than in those receiving double CBT (P=0.02), and in those given in vivo T-cell depletion 
of the donor graft (P=0.006). 
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Engraftment and GVHD 
At 60 days after CBT, neutrophil engraftment was achieved by 91% (95% CI 87%-94%) 
of MRD negative patients versus 85% (95% CI 79%-90%) of those with measurable 
MRD (P=0.05). The 100-day cumulative incidences of grade II-IV and of III-IV acute 
GVHD were 34% (95% CI 28%-39%) and 15% (95% CI 11%-19%) respectively, in MRD 
negative patients, versus 37% (95% CI 29%-44%, P=0.5) and 16% (95% CI 11%-22%, 
P=0.6). On multivariate analysis, the only factor associated with a lower incidence of 
grade II-IV acute GVHD was in vivo T cell depletion (HR=0.5, 95% CI 0.4-0.8, P=0.001) 
(Supplemental table 2). 
 The 2-year cumulative incidences of chronic and extensive chronic GVHD were 
33% (95% CI 27%-38%) and 12% (95% CI 8%-16%) respectively in MRD negative 
patients, versus 25% (95% CI 18%-32%, P=0.2) and 13% (95% CI 8%-19%, P=0.4). On 
multivariate analysis, no factor was associated with chronic GVHD. 
 
Relapse and NRM 
At 2 years, relapse incidence was 18% (95% CI 14%-22%) in patients with MRD 
negativity versus 33% (95% CI 26%-41%, P<0.001) in those with MRD positivity at 
transplantation (Figure 1). This negative effect of MRD positivity on relapse was 
observed both in patients with AML and in those with ALL (independently of Phi 
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positivity), and was also observed both in patients in first CR and in those in second CR 
(Supplemental Tables 3-6). In the subgroup of patients with AML, poor risk cytogenetics 
(according to the MRC classification32) was associated with higher relapse incidence in 
comparison to good/intermediate risk cytogenetics (at 2-year 29% (95% CI, 16%-43%) 
vs 22% (95%CI, 15%-29%), P=0.02). Restricting the analyses in AML patients with 
good/intermediate risk cytogenetics (n=271), MRD positivity (n=82) remained 
significantly associated with a higher risk of relapse (28% (95% CI, 18%-38%) vs 16% 
(95% CI, 11%-22%), P=0.046; supplemental table 7).  On multivariate analysis, MRD 
positivity was associated with an increased risk of relapse (HR=1.8, 95% CI 1.2-2.6, 
P=0.003) (Table 2). Other factors associated with risk of relapse included the use of RIC 




Two-year LFS was 57% (95%CI, 51%-63%) in MRD negative patients versus 38% 
(95%CI, 30%-45%) in those with MRD positivity at CBT (P<0.001) (Figure 1). There was 
no statistical interaction between any variable and the association of MRD status with 
LFS. Furthermore, as shown in Figure 2, detectable MRD at transplantation was 
associated with worse (or a trend towards worse) LFS in each assessed subgroup (single 
versus double CBT, AML versus ALL, Phi positive versus Phi negative ALL). Specifically, 
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among ALL patients, 2-year LFS was 55% (95%CI, 46%-65%) in MRD negative patients 
versus 33% (95%CI, 22%-44%) in MRD positive ones (P=0.002) while among AML 
patients the figures were 58% (95%CI, 51%-65%) versus 41% (95%CI, 31%-52%), 
respectively (P=0.02). Restricting the analyses to AML patients with good/intermediate 
risk cytogenetics32, 2-year LFS was 59% (95% CI, 51%-66%) in MRD negative patients, 
versus 44% (95% CI, 32%-55%, P=0.019) in MRD positive ones. Further, interestingly, 
the negative impact of MRD positivity was at least as much marked in patients in second 
CR than in those in first CR (Figure 2). Importantly, MRD positivity remained associated 
with a worse LFS on multivariate analysis (HR=1.42, 95% CI1.1-1.84 P=0.008). Other 
factors associated with LFS included second versus first CR at transplantation (HR=1.33, 
95%CI 1.01-1.76, p=0.04) and in vivo T cell depletion (HR=1.92, 95% CI 1.41-2.61, 
P=0.014) (Table 2).   
 Two-year GRFS was 43% (95%CI, 37%-49%) in MRD negative patients versus 
31% (95%CI, 24%-38%) in those with MRD positivity at CBT (P=0.005) (Figure 1). 
There was no statistical interaction between diagnostic group and the association of 
MRD status with GRFS. Specifically, among ALL patients, 2-year GRFS was 37% (95%CI, 
28%-50%) in MRD negative patients versus 27% (95%CI, 16%-37%) in MRD positive 
ones (P=0.08) while among AML patients the figures were 46% (95%CI, 39%-53%) 
versus 35% (95%CI, 24%-45%), respectively (P=0.046). On multivariate analysis MRD 
positivity at transplantation was associated with worse GRFS (HR=1.3, 95%CI 1.03-1.65, 
P=0.029). No other factor was significantly associated with GRFS.  
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OS 
Two-year OS was 60% (95%CI, 55%-66%) in MRD negative patients versus 48% (95%CI, 
39%-56%) in those with MRD positivity at CBT (P=0.004) (Figure 1). There was no 
statistical interaction between diagnostic group and the association of MRD status with 
OS (Figure). Among ALL patients, the 2-year OS was 60% (95%CI, 50%-69%) in MRD 
negative patients versus 47% (95%CI, 35%-59%) in MRD positive ones (P=0.02) while 
among AML patients the figures were 60% (95%CI, 53%-67%) versus 48% (95%CI, 
37%-59%), respectively (P=0.049). Restricting the analyses to AML patients with 
good/intermediate risk cytogenetics32, 2-year OS was 62% (95% CI, 54%-69%) in MRD 
negative patients, versus 50% (95% CI, 37%-61%, P=0.034) in MRD positive ones. 
Further, interestingly, the negative impact of MRD positivity was as much marked in 
patients in second CR as it was in those in first CR (Figure 2).  On multivariate analysis 
there was a trend for worse OS in patients with detectable MRD (HR=1.3, 95%CI 0.98-
1.71, P=0.065). Other factors associated with OS included older age (per decade, 
HR=1.13, 95% CI 1.01-1.27, P=0.03), second versus first CR at transplantation (HR=1.45, 
95%CI 1.08-1.94, p=0.01) and in vivo T cell depletion (HR=1.78, 95% CI 1.28-2.47, 
P<0.001) (Table 2).   
 At the time of analysis, death from the underlying disease of MRD negative and 
MRD positive patients was 14% and 18% respectively, while 5% and 11% respectively, 
died from GVHD. 
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DISCUSSION 
Several reports have demonstrated the negative impact of detectable MRD at 
transplantation on transplantation outcomes in patients given grafts from HLA-matched 
or HLA-haploidentical donors19,20,27,28. However, the impact of detectable MRD at 
transplantation on CBT outcome remains debatable. Tucunduva et al. first reported that 
in the setting of Phi-positive ALL (n=98), detectable MRD (n=59) was associated with a 
higher risk of relapse following CBT 33. In contrast, a study by Milano et al. of data from 
137 patients with AML, ALL or myelodysplastic syndrome, reported that detectable 
MRD at transplantation (n=45) was not associated with a significantly higher risk of 
relapse following double CBT (HR=1.43, 95% CI : 0.58-3.57). The authors also reported a 
lower incidence of relapse with double CBT than with HLA-matched or HLA-mismatched 
transplantation, among MRD positive patients15. These data, which are in line with 
emerging data suggesting higher GvL effects in (double) CBT34-36, prompted us to assess 
the impact of detectable MRD on CBT outcomes in a relatively large cohort of patients 
with AML or ALL in first or second CR at transplantation.  
 First, we observed that detectable MRD at CBT was associated with higher risk of 
relapse leading to worse LFS, worse GRFS and a suggestion for worse OS. This impact of 
detectable MRD was observed in all subgroups but perhaps appeared to be less marked 
among patients with Phi-positive ALL, possibly because many of these patients might 
have received a tyrosine kinase inhibitor after CBT (or possibly due to a lack of 
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statistical power in subgroup analyses). Interestingly, the impact of detectable MRD at 
CBT was at least as strong in patients in CR2 at transplantation as in those in first CR. 
Nevertheless, despite detectable MRD at transplantation being associated with poorer 
CBT outcomes it should be stressed that CBT outcomes among MRD positive patients 
remained encouraging with approximately half of the patients still alive 2 years after 
CBT.  
 This study also confirms several observations made previously regarding CBT for 
acute leukemia such as similar LFS with both RIC and MAC regimens 29,37, similar LFS 
with double or single unit CBT 10,38, and a detrimental impact of in vivo T-cell depletion 
on CBT outcome 18,39,40. 
 There are some limitations to our study including the fact that MRD assessment 
was not standardized and that the method of MRD detection varied among centres, or 
the fact that we lack data on the use of post-transplant anti-leukemia agents (such as 
tyrosine kinase inhibitor in case of Phi-positive ALL or FLT3-mutated AML5,41,42, or 
hypomethylating agents43,44).  
 
CONCLUSIONS 
In summary, our results indicate that among acute leukemia patients undergoing CBT, 
achieving MRD negativity at time of transplantation is associated with a lower risk of 
relapse translating into better LFS. Novel strategies are needed for those leukemic 
patients with MRD positivity pre-CBT aiming at either achieving MRD negativity at CBT 
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or preventing relapse following CBT by receiving post-transplant anti-leukemic drugs 
and/or immunotherapy and thus further improving CBT results. 
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FIGURE LEGEND 
Figure 1. Impact of MRD on transplantation outcomes. A) relapse. B) non relapse 
mortality. C) leukemia-free survival. D) GVHD-free and relapse-free survival. E) overall 
survival. 
Figure 2. Forest-plot showing the impact of detectable MRD (versus not) on leukemia-
free survival (A, LFS) and overall survival (B, OS) in various subgroups. 
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Table 1. Patient and transplant characteristics 






Median patient age, y (range) 43 (18-70) 41 (18-66) 0.46 
Patient sex, # (%)   0.73 
    Male 168 (50) 87 (51)  
    Female 169 (50) 82 (49)  
KPS, # (%)   0.51 
   < 80 11 (4) 4 (2)  
   >= 80 291 (96) 156 (98)  
   Missing 35 9  
    
Diagnosis, # (%)   0.023 
    AML 223 (66) 94 (56)  
          Good risk2 23 20  
          Intermediate risk2 87 43  
          Poor risk2 34 12  
          NA / failed 79 19  
    ALL 114 (34) 75 (44)  
           Phi neg B ALL 16 8  
           Phi pos B ALL 53 49  
           T ALL 19 9  
           ALL missing 26 9  
Status at transplantation, # (%)   0.42 
     CR1 209 (62) 111 (66)  
     CR2 128 (38) 58 (34)  
Follow-up, mo (IQR) 40 (19-74) 53 (19-70)  
Conditioning regimen, # (%)   0.10 
     Myeloablative 202 (60) 114 (67)  
           TBI based 105 (31) 56 (33)  
           TBF 70 (21) 43 (25)  
           BuCy 






     Reduced-intensity 135 (40) 55 (33)  
           TBI based 123 (36) 46 (27)  
           Other / missing 12 (4) 9 (5)  
In vivo TCD, # (%)   0.006 
   Yes 203 (64) 82 (51)  
   No 116 (36) 80 (49)  
   Missing 18 7  
Units of  CBT      0.02 
    Single  139 (41) 88 (52)  
    Double  198 (59) 81 (48)  
Postgrafting immunosuppression, 
# (%) 
  0.9 
     CSP alone 69 (22) 41 (25)  
     CSP + MMF +/- MTX 211 (66) 102 (63)  
     Other  40 (12) 19 (11)  
     Missing 17 7  
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1, calculated with χ2 statistics for categorical variables and Mann-Whitney test for continuous variables; 2, 
cytogenetic risk was categorized according to the MRC classification32; 3, refers to the comparison of AML 
versus ALL; Y, year; mo, month; KPS, Karnofsky score, AML, acute myeloid leukemia; ALL, acute 
lymphoblastic leukemia; Phi, Philadelphia chromosome; TBI, total body irradiation; TBF, thiotepa, 
busulfan and fludarabine; BuCy, busulfan and cyclophosphamide; IQR, interquartile range; CR, complete 
remission; TCD, T-cell depletion; CBT, cord blood transplantation; #, number of patients; tacro, 
tacrolimus; CSP, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate. 
 
 
Table 2: Multivariate analyses for CBT outcomes. 
 
 
RELAPSE NRM LFS OS GRFS 
 
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
MRD detectable vs not 1.78 (1.22-2.58) 0.003 1.15 (0.80-1.66) 0.44 1.42 (1.1-1.84) 0.008 1.3 (0.98-1.71) 0.065 1.3 (1.03-1.65) 0.029 
ALL vs AML 1.33 (0.88-2.03) 0.181 1.14 (0.77-1.69) 0.521 1.22 (0.92-1.63) 0.168 1.09 (0.8-1.48) 0.592 1.21 (0.94-1.57) 0.135 
Age (per 10 years) 0.99 (0.85-1.16) 0.91 1.16 (1-1.35) 0.047 1.08 (0.97-1.2) 0.169 1.13 (1.01-1.27) 0.031 1.04 (0.95-1.15) 0.403 
Year of CBT 0.99 (0.93-1.06) 0.82 0.96 (0.91-1.02) 0.207 0.98 (0.94-1.02) 0.273 0.97 (0.925-1.01) 0.17 0.99 (0.95-1.03) 0.594 
CR2 vs CR1 1.31 (0.87-1.99) 0.193 1.35 (0.93-1.98) 0.119 1.33 (1.01-1.76) 0.043 1.45 (1.08-1.94) 0.013 1.26 (0.99-1.62) 0.064 
RIC vs MAC 1.84 (1.16-2.92) 0.01 0.829 (0.52-1.32) 0.43 1.23 (0.89-1.7) 0.221 1.06 (0.75-1.5) 0.741 0.93 (0.69-1.24) 0.616 
DCBT vs SCBT 1.0 (0.65-1.52) 0.992 0.71 (0.48-1.05) 0.089 0.83 (0.63-1.11) 0.216 0.75 (0.55-1.02) 0.067 0.91 (0.70-1.18) 0.476 
in vivo TCD 2.18 (1.39-3.41) 0.001 1.69 (1.11-2.58) 0.014 1.92 (1.41-2.61) <0.001 1.78 (1.28-2.47) 0.001 1.17 (0.89-1.55) 0.261 
Centre (frailty)   0.924   0.357   0.905   0.701   0.898 
 
NRM, non relapse mortality; LFS, leukemia-free survival; OS, overall survival; GRFS, GVHD-free and 
relapse free survival; MRD, minimal residual disease; ALL, acute lymphoblastic leukemia; AML, acute 
myeloid leukemia; CBT, cord blood transplantation; CR, complete remission; RIC, reduced-intensity 
conditioning regimen; MAC, myeloablative conditioning regimen; dCBT, double unit CBT; sCBT, single unit 
CBT; TCD, T-cell depletion; HR, hazard ratio; CI, confidence interval. 
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